XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies

XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies

ABSTRACT The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures. First-generation coronavirus disease 2019 (COVID-19) vaccines encoded an ancestral spike protein. Updated bivalent vaccines...

Full description

Saved in:
Bibliographic Details
Main Authors: Juan Manuel Carreño, Brian Lerman, Gagandeep Singh, Anass Abbad, Temima Yellin, Jordan Ehrenhaus, Miriam Fried, Jessica R. Nardulli, Hyun Min Kang, Lubbertus C. F. Mulder, Charles Gleason, Komal Srivastava, Viviana Simon, Florian Krammer
Format: Article
Language:English
Published: American Society for Microbiology 2025-04-01
Series:mBio
Subjects:
SARS-CoV-2
cross-reactive immune responses
COVID-19 vaccine
XBB.1.5 monovalent vaccine
imprinting
Online Access:https://journals.asm.org/doi/10.1128/mbio.03607-24
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.asm.org/doi/10.1128/mbio.03607-24

Similar Items